Scopus BioPharma Inc.

SCPS

US8091711015

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:49:55 2024-05-09 EDT			5-day change	1st Jan Change
0.0011 ^USD	-47.62%		0.00%	-97.45%

2023	Scopus BioPharma Inc. Presents DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma	CI
2023	Scopus BioPharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Scopus BioPharma Inc.(NasdaqCM:SCPS) dropped from S&P TMI Index

December 21, 2022 at 12:00 am

Latest news about Scopus BioPharma Inc.

Scopus BioPharma Inc. Presents DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma	11-07	CI
Scopus BioPharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Scopus BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Scopus BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Scopus BioPharma Inc. Auditor Raises 'Going Concern' Doubt	23-04-13	CI
Scopus BioPharma Inc.(NasdaqCM:SCPS) dropped from S&P TMI Index	22-12-21	CI
Scopus BioPharma Inc.(NasdaqGM:SCPS) dropped from NASDAQ Composite Index	22-12-16	CI
Weaker-Than-Expected Retail Sales, Hawkish Fed Send US Stock Futures Sharply Lower	22-12-15	MT
Federal Reserve's Still-Hawkish Stance Appears to Disappoint Investors; US Futures Move Lower	22-12-15	MT
Top Premarket Gainers	22-12-15	MT
Scopus BioPharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
Scopus BioPharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Top Premarket Decliners	22-07-11	MT
Scopus BioPharma Inc. Announces Resignation of Paul Hopper from Board of Directors	22-05-20	CI
Scopus BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-19	CI
Scopus Biopharma Inc. Announces Resignation of Ashish Sanghrajka from the Board of Directors with Effect from May 11, 2022	22-05-13	CI
Scopus BioPharma Inc. Appoints Raphael Hofstein to its Board of Directors	22-05-05	CI
Scopus Biopharma Inc. Announces Board Resignations	22-04-29	CI
Scopus BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Scopus BioPharma Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Scopus BioPharma Announces the Final Results	22-01-10	CI
Scopus BioPharma Inc. Announces Board Appointments	22-01-06	CI
Declaration of Preliminary Voting Results by Scopus BioPharma	21-12-27	CI
Scopus BioPharma Sends Letter to its Shareholders	21-12-17	CI
Scopus BioPharma Sends Letter to its Shareholders	21-12-07	CI

Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs. The Companyâs Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SCOPUS BIOPHARMA INC.	-97.45%	46.29K
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs